Dr. Chukwueke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-6177
Education & Training
University of Texas Southwestern Medical CenterResidency, Neurology, 2011 - 2015
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2011
Certifications & Licensure
NH State Medical License 2024 - 2026
RI State Medical License 2020 - 2026
CT State Medical License 2022 - 2025
MA State Medical License Active through 2025
PA State Medical License 2015 - 2016- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas Start of enrollment: 2019 Jul 12
Roles: Principal Investigator, Contact
- Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Start of enrollment: 2021 Mar 08
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 15 citationsSocioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma.Nayan Lamba, Ugonma Chukwueke, Timothy R. Smith, Keith L. Ligon, Ayal A. Aizer
JAMA Oncology. 2020-12-01 - 161 citationsGenomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinomaDavid Shih, Naema Nayyar, Ivanna Bihun, Ibiayi Dagogo-Jack, Corey M. Gill
Nature Genetics. 2020-03-23 - 43 citationsPhase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Q. Lee, Nancy Wang, Justine V. Cohen
Nature Communications. 2021-10-12
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
